Table 2.

Trials of long-term β-adrenoceptor blockade in secondary prevention after myocardial infarction.

Trial	Drug/dose	Patients/duration	Reinfarction	Mortality
Norwegian Multicentre	Timolol	1884	14.4% vs 20.1%	10.6% vs 17.4%
1985 [20]	10 mg bd	17 months	RR 28.4%	RR 39% (P = 0.0005)
BHAT	Propranolol	3837	4.4% vs 5.3%	7.2% vs 9.8%
1982 [21]	60–80 mg tds	25 months	RR 16% (NS)	RR 26% (P < 0.05)
ISIS-1	Atenolol	16027		10.7% vs 12.0% ⋆
1986 [22]	100 mg od#	12 months		RR 11% (2P < 0.01)
Lopressor Intervention	Metoprolol	2395		5.6 vs 5.2%
Trial 1987 [23]	100 mg bd	12 months		RR −5% (NS)
EIS Group	Oxprenolol	1741	6.2% vs 5.1%	2.9% vs 2.7%
1984 [24]	160 mg bd	12 months	RR −22% (ns)	RR −7.4% (NS)
Australian/Swedish	Pindolol	529	14.1% vs 15.4%	10.6% vs 11.7%
1983 [25]	15 mg od	24 months	RR 8% (NS)	RR 5% (NS)
APSI Study	Acebutolol	607		5.8% vs 12%
1997 [26]	200 mg bd	12 months		RR 48% (P < 0.01)

^⋆vascular mortality

^#open control/atenolol for 7 days postinfarct.

NS = nonsignificant.